The phosphoinositide 3-kinase a selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells

Molecular Cancer Therapeutics

Volumn 13, Issue 5, 2014, Pages 1044-1053

  Musi, Elgilda ^a   Ambrosini, Grazia ^a   De Stanchina, Elisa ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BYL 719; MARCKS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C; SOTRASTAURIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GNA11 PROTEIN, HUMAN; GNAQ PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; NVP-BYL719; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL DEATH; CELL MUTANT; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; FEMALE; GENE MUTATION; GROWTH INHIBITION; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; UVEA MELANOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE SILENCING; GENETICS; HUMAN; MELANOMA; MUTATION; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME; UVEAL NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE SILENCING; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; MELANOMA; MICE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE C; PYRROLES; QUINAZOLINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THIAZOLES; TUMOR BURDEN; UVEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899863027     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0550     Document Type: Article

References (44)

1. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009;148:119-27.
2. Patel M, Smyth E, Chapman PB, Wolchok JD, Schwartz GK, Abramson DH, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res 2011;17:2087-100.
3. Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel MB, et al. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 2003;83:1771-6.
4. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005;92:2032-8.
5. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
6. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:5230-4.
7. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-9.
8. Rozengurt E. Mitogenic signaling pathways induced by G proteincoupled receptors. J Cell Physiol 2007;213:589-602.
9. Martiny-Baron G. Classical PKC isoforms in cancer. Pharmacol Res 2007;55:477.
10. Thelen M, Rosen A, Nairn AC, Aderem A. Regulation by phosphorylation of reversible association of a myristoylated protein kinase C substrate with the plasma membrane. Nature 1991;351: 320-2.
11. Hartwig JH, Thelen M, Rosen A, Janmey PA, Nairn AC, Aderem A. MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. Nature 1992;356:618-22.
12. Graff JM, Young TN, Johnson JD, Blackshear PJ. Phosphorylationregulated calmodulin binding to a prominent cellular substrate for protein kinase C. J Biol Chem 1989;264:21818-23.
13. Ballou LM, Chattopadhyay M, Li Y, Scarlata S, Lin RZ. Galphaq binds to p110a/p85a phosphoinositide 3-kinase and displaces Ras. Biochem J 2006;394:557-62.
14. Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, et al. Involvement of PI3K/ Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci 2008;49: 497-504.
15. Stephens L, Williams R, Hawkins P. Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 2005;5:357-65.
16. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/ AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4:988-1004.
17. Matheny RW Jr., Adamo ML. PI3K p110a and p110b have differential effects on Akt activation and protection against oxidative stressinduced apoptosis in myoblasts. Cell Death Differ 2010;17:677-88.
18. Saraiva VS, Caissie AL, Segal L, Edelstein C, Burnier MNJr. Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res 2005;15:245-50.
19. Populo H, Soares P, Rocha AS, Silva P, Lopes JM. Evaluation of the mTORpathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 2010;20:107-17.
20. Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012;10:161.
21. Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 2012;7:e29622.
22. Wu X, Li J, Zhu M, Fletcher JA, Hodi FS. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kB pathways. Mol Cancer Ther 2012;11:1905-14.
23. Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L, et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011;71:2643-53.
24. Huang A FC, Wilson C, Reddy A, Liu M, Lehar J, et al. Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR;
25. Cancer Res 2012;72(8 Suppl):Abstract nr 3749.
26. Furet P, Guagnano V, Fairhurst RA, Imbach-Weese P, Bruce I, Knapp M, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol- 3 kinase a inhibitor selected for clinical evaluation. Bioorg Med Chem Lett 2013;23:3741-8.
27. Ambrosini G, Musi E, Ho AL, de Stanchina E, Schwartz GK. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol Cancer Ther 2013;12:768-76.
28. Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, et al. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res 2012;25:182-7.
29. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
30. Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther 2008;7:890-6.
31. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999;5:1876-83.
32. Nair JS, de Stanchina E, Schwartz GK. The topoisomerase I Poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res 2009;15:2022-30.
33. Amaro A, Mirisola V, Angelini G, Musso A, Tosetti F, Esposito AI, et al. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity. Eur J Cancer (Oxford, England: 1990) 2013;49:3353-65 33.
34. Brady SW, Zhang J, Seok D, Wang H, Yu D. Enhanced PI3K p110alpha signaling confers acquired lapatinib resistance which can be effectively reversed by a p110alpha-selective PI3K inhibitor. Mol Cancer Ther 2014;13:60-70.
35. Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F. The PI3K/ Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Invest Ophthalmol Vis Sci 2010; 51:421-9.
36. Carvajal RD A, Wolchok JD, Chapman PB, Dickson MA, D'Angelo SP, et al. Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma. J Clin Oncol 2012;30:15s (suppl; abstr 8598).
37. Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, et al. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 2012;7:e40439.
38. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 2012;18:4345-55.
39. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
40. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee WJ, et al. A drug targeting only p110alpha can block phosphoinositide 3- kinase signalling and tumour growth in certain cell types. The Biochemical journal 2011;438:53-62.
41. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase-moving towards therapy. Biochim Biophys Acta 2008;1784:159-85.
42. Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene. Epub 2013 Oct 21.
43. Wen HC, Huang WC, Ali A, Woodgett JR, Lin WW. Negative regulation of phosphatidylinositol 3-kinase and Akt signalling pathway by PKC. Cell Signal 2003;15:37-45.
44. Roy S, Srivastava R, Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010;5:10.